Mirikizumab
drugOn this page
Also known as LY-3074828LY3074828Mirikizumab-mrkzOmvoh
Summary
Mirikizumab (CHEMBL3990014) is an approved antibody (ATC L04AC24); indicated across 5 conditions including crohn disease and ulcerative colitis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC24
- Indications: 5 conditions
- Clinical trials: 39
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3990014 |
| Name | Mirikizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC24 |
Also known as: LY-3074828, LY3074828, Mirikizumab, Mirikizumab-mrkz, Omvoh, MIRIKIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Crohn disease | 4 | MONDO:0005011 | EFO:0000384 |
| ulcerative colitis | 4 | MONDO:0005101 | EFO:0000729 |
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| psoriasis | 3 | MONDO:0005083 | EFO:0000676 |
| inflammatory bowel disease | 3 | MONDO:0005265 | EFO:0003767 |
Clinical trials
Total trials: 39.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 15 |
| PHASE3 | 12 |
| PHASE2 | 6 |
| PHASE4 | 5 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06997965 | PHASE4 | NOT_YET_RECRUITING | Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD |
| NCT07059130 | PHASE4 | NOT_YET_RECRUITING | Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn’s Disease and Ulcerative Colitis |
| NCT07235904 | PHASE4 | RECRUITING | Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis |
| NCT07612267 | PHASE4 | NOT_YET_RECRUITING | A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication |
| NCT06626165 | PHASE4 | COMPLETED | Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa |
| NCT03519945 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) |
| NCT04232553 | PHASE3 | ACTIVE_NOT_RECRUITING | A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease |
| NCT04844606 | PHASE3 | RECRUITING | A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn’s Disease (SHINE-ON) |
| NCT05509777 | PHASE3 | RECRUITING | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn’s Disease |
| NCT05767021 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
| NCT06937086 | PHASE3 | RECRUITING | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study |
| NCT06937099 | PHASE3 | RECRUITING | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight |
| NCT03482011 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis |
| NCT03518086 | PHASE3 | COMPLETED | An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) |
| NCT03535194 | PHASE3 | COMPLETED | A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) |
| NCT03556202 | PHASE3 | TERMINATED | A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) |
| NCT03926130 | PHASE3 | COMPLETED | A Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease |
| NCT06598943 | PHASE2 | RECRUITING | A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis |
| NCT07186101 | PHASE2 | RECRUITING | LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: |
| NCT02589665 | PHASE2 | COMPLETED | A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis |
| NCT02891226 | PHASE2 | COMPLETED | A Study of Mirikizumab (LY3074828) in Participants With Active Crohn’s Disease |
| NCT02899988 | PHASE2 | COMPLETED | A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis |
| NCT04004611 | PHASE2 | COMPLETED | A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) |
| NCT07446101 | PHASE1 | RECRUITING | A Study of Mirikizumab Solution (LY3074828) in Healthy Participants |
| NCT03053622 | PHASE1 | COMPLETED | A Study of Mirikizumab (LY3074828) Injection in Healthy Participants |
| NCT03188510 | PHASE1 | COMPLETED | A Study of Two Different Formulations of LY3074828 in Healthy Participants |
| NCT03220126 | PHASE1 | COMPLETED | A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants |
| NCT03456713 | PHASE1 | COMPLETED | A Study of LY3074828 in Healthy Participants |
| NCT03662100 | PHASE1 | COMPLETED | A Study of Two Formulations of LY3074828 in Healthy Participants |
| NCT03718884 | PHASE1 | COMPLETED | A Study of Mirikizumab in Participants With Plaque Psoriasis |
| NCT03748940 | PHASE1 | COMPLETED | Study of LY3074828 in Healthy Participants |
| NCT03886948 | PHASE1 | COMPLETED | A Study of Injections of LY3074828 in Healthy Participants |
| NCT04548219 | PHASE1 | COMPLETED | A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants |
| NCT04607733 | PHASE1 | COMPLETED | A Study of Mirikizumab in Healthy Participants |
| NCT05069896 | PHASE1 | COMPLETED | A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants |
| NCT05515601 | PHASE1 | COMPLETED | A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants |
| NCT05644353 | PHASE1 | COMPLETED | A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants |
| NCT06475729 | PHASE1 | COMPLETED | A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants |
| NCT06249555 | Not specified | RECRUITING | VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn’s Disease: A Prospective Observational Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).